PT - JOURNAL ARTICLE AU - KIRAN YALAMANCHILI AU - JUDY LALMUANPUII AU - FAISAL WAHEED AU - SASSAN FARJAMI AU - RAM KANCHERLA AU - ZEESHAN QURESHI AU - ALBERT HOANG AU - YUSUF KHALED AU - DIANA LAKE AU - CARMELLO PUCCIO AU - HOO G. CHUN AU - KAREN SEITER AU - TAUSEEF AHMED TI - High-dose Chemotherapy with Autologous Stem Cell Rescue in Stage IIIB Inflammatory Breast Cancer DP - 2008 Sep 01 TA - Anticancer Research PG - 3139--3142 VI - 28 IP - 5B 4099 - http://ar.iiarjournals.org/content/28/5B/3139.short 4100 - http://ar.iiarjournals.org/content/28/5B/3139.full SO - Anticancer Res2008 Sep 01; 28 AB - Background: Despite the advances in breast cancer care, inflammatory breast cancer (IBC) has a poor prognosis. The purpose of this study was to determine the efficacy of high-dose chemotherapy (HDCT) with thiotepa, mitoxantrone and carboplatin (TMJ regimen) in women with TNM stage IIIB IBC. Patients and Methods: Between 1991 and 1998, twenty-eight patients with stage IIIB IBC underwent an autologous stem cell transplant after undergoing chemotherapy, surgery and/or radiation. Stem cells were collected from the bone marrow and periphery after mobilization with growth factors. Patients received thiotepa 250 mg/m2 once daily i.v. for 3 days, mitoxantrone 40 mg/m2 for 1 day and carboplatin 333 mg/m2 once daily i.v. for 3 days as the conditioning regimen for the HDCT. Radiation therapy and tamoxifen was offered to patients post HDCT if appropriate. Progression-free survival and overall survival was assessed over a 15-year period. Results: At the time of last follow-up in May, 2007, sixteen patients had relapsed. The median overall survival was 49.5 months. The median progression free survival was 40 months. There were no transplant-related deaths. Mucositis and infections were the major side-effects. These results show that HDCT with the TMJ regimen is safe and effective in patients with stage IIIB IBC. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved